Tylenol Autism Lawsuits Reinstated in 2026: 500+ Cases Revived After Appeals Court Reversal
In July 2026, the Court of Appeals for the Second Circuit reinstated more than 500 Tylenol autism and ADHD lawsuits, reversing the 2024 federal dismissal. On October 16, 2026, the court rejected the manufacturers' request for rehearing, sending the cases back to Judge Denise Cote in New York. No verdict or settlement has occurred, but the litigation is alive again.
Key facts
- MDL No. 3043 — In re: Acetaminophen – ASD/ADHD Products Liability Litigation — was formed in October 2022 in the Southern District of New York under Judge Denise L. Cote.
- In December 2023, Judge Cote excluded the plaintiffs' causation experts under the Daubert standard, the federal test for whether expert testimony is scientifically reliable enough for a jury.
- In August 2024, with no admissible causation evidence left, the court granted summary judgment for the manufacturers — until the appeal.
- On July 13, 2026, the Second Circuit reversed, ruling three experts were wrongly excluded; on October 16, 2026, it denied rehearing.
- In September 2025, the FDA announced plans to update acetaminophen labels about a possible association with autism or ADHD, while stating causation was not established.
For plain-English video briefings on money and law topics, subscribe to Problem Solved.
What the Lawsuits Actually Claim
Acetaminophen is the active ingredient in Tylenol and hundreds of generic pain relievers. The lawsuits allege the manufacturers — including Johnson & Johnson, its former consumer-health arm Kenvue, and store-brand sellers — failed to warn that prenatal use might increase the risk of autism spectrum disorder or ADHD in children. The legal theories are failure to warn, negligent marketing, and strict product liability. Every defendant disputes the claims. Our original Tylenol autism lawsuit explainer covers who qualifies and how the claims are structured.
How the Cases Died: December 2023 to August 2024
Product-liability cases live or die on expert testimony, and this one died on it twice. After the October 2022 consolidation, both sides prepared scientific experts for a Daubert hearing — the pretrial proceeding where the judge decides whether an expert's methods are reliable enough for a jury. On December 18, 2023, Judge Cote excluded the plaintiffs' causation experts. Without admissible experts connecting prenatal acetaminophen exposure to autism or ADHD, the central element of the case could not be proven. In August 2024, the court granted summary judgment for the manufacturers — the ruling that ends a case before trial when no reasonable jury could find for the other side. Plaintiffs appealed immediately.
The July 2026 Reversal: What the Appeals Court Decided
On July 13, 2026, a three-judge panel of the Second Circuit reversed the dismissal, holding that three plaintiffs' experts had been wrongly excluded — their methods were sufficiently reliable to be heard, even though the underlying science remains contested. More than 500 cases were reinstated and returned to Judge Cote. Two points are widely misunderstood. First, reversing a Daubert exclusion is not a finding that Tylenol causes autism or ADHD; it is a ruling that a jury may hear the argument. Second, reversal does not guarantee a trial — Judge Cote will conduct further pretrial proceedings, and the admissibility of the evidence remains an open question.
October 16, 2026: Rehearing Denied — What Happens Next
The manufacturers asked the Second Circuit to reconsider its July ruling. On October 16, 2026, the court said no. The cases now return to Judge Cote for renewed expert proceedings, discovery, and eventually the selection of bellwether trials — representative test cases whose outcomes usually set the tone for settlement talks across a multidistrict litigation. No trial dates have been set, no settlement negotiations announced, and no compensation paid to any plaintiff. That is the honest state of play: resurrected, but still pretrial. A parallel path exists in state courts, where some plaintiffs may file individual claims outside the federal MDL, though those face their own evidentiary battles.
Do You Have a Claim? The Honest Checklist
Attorneys evaluating potential claims look for the same basic facts: the mother used acetaminophen during pregnancy, and the child was later diagnosed with autism or ADHD. Medical records documenting both are essential, and timing matters — statutes of limitations, the legal deadlines for filing, vary by state and can be complicated by rules pausing the clock while a child is a minor. If that describes your family, the practical step is a free consultation with a product-liability attorney experienced in multidistrict litigation — most work on contingency, meaning they are paid only if the case succeeds. What no honest attorney will do is promise an outcome: with no verdicts or settlements to date, any prediction would be speculation. Our hair relaxer MDL update and Paraquat status report show how these long litigations typically evolve.
The Science Is Still Disputed — Read Every Headline Twice
Several observational studies have found an association between frequent prenatal acetaminophen use and higher rates of autism or ADHD diagnoses. An association is not causation: the two appear together more often than chance predicts, but the underlying illness that prompted the drug use could explain part of the pattern. In September 2025, the FDA announced plans to update acetaminophen warning labels to mention the possible association, explicitly stating causation had not been established. The manufacturers continue to dispute any causal link. Remember: a courtroom is not a laboratory. Judges decide which evidence a jury may hear, not which scientific theory is true. Treat every headline about this litigation — in either direction — as a report on procedure, not on medicine.
Who Benefits From This — and Who Does Not
Who benefits most from this guide:
Families where the mother used acetaminophen during pregnancy and the child was later diagnosed with autism or ADHD, with records documenting both How: attorneys evaluating potential claims look for those same basic facts, and medical records documenting both are essential
Families filing in the revived federal MDL or in state courts How: on July 13, 2026 the Second Circuit reinstated more than 500 cases, and on October 16, 2026 it denied the manufacturers' request for rehearing, returning the cases to Judge Cote, while state-court filings remain an option
Families who get their timing assessed promptly How: statutes of limitations vary by state and can be complicated by rules pausing the clock while a child is a minor, so a prompt free consultation is the practical step
Who does not benefit:
Anyone expecting a verdict, a settlement, or a predicted outcome How: no case has gone to trial and no verdict or settlement has been reached, so with nothing to report yet any prediction would be speculation
Anyone claiming causation is proven How: causation has not been established: some studies show an association, the FDA announced in September 2025 that it plans to update labels to mention the possible association while stating causation is unproven, and the manufacturers dispute the claims
Anyone without documented exposure and diagnosis records How: both elements are essential to an evaluation, so a claim built on neither fits poorly
For the companion ADHD cases in the same MDL, see our Tylenol autism lawsuit guide.
Frequently Asked Questions
Did anyone win a Tylenol autism lawsuit?
No. No case has gone to trial, and no verdict or settlement has been reached. Compensation varies widely by case, and most settlements are confidential — but in this litigation there is nothing to report yet.
What did the appeals court rule in July 2026?
On July 13, 2026, the Second Circuit ruled that the MDL judge had wrongly excluded three of the plaintiffs' causation experts, reversed the 2024 dismissal, and reinstated more than 500 cases. On October 16, 2026, it denied the manufacturers' request for rehearing, returning the cases to Judge Cote.
Does taking Tylenol during pregnancy cause autism or ADHD?
Causation has not been established. Some studies show an association; the FDA announced in September 2025 that it plans to update labels to mention the possible association while stating causation is unproven. The manufacturers dispute the claims.
Can I still file a Tylenol autism claim in 2026?
Possibly. The federal MDL was revived in July 2026, and state-court filings remain an option. Statutes of limitations vary by state and can be affected by minority-tolling rules, so consult a product-liability attorney promptly.
This article is general information, not legal, medical, or financial advice. Court proceedings and scientific understanding evolve — consult a qualified attorney about your own situation before acting.
Who benefits from a Tylenol autism claim, and who does not?
Families where the mother used acetaminophen during pregnancy and the child was later diagnosed with autism or ADHD benefit most, when medical records document both and the timing is assessed promptly, since the federal MDL was revived in July 2026 and state-court filings remain an option. People expecting a verdict, a settlement, or a predicted outcome do not benefit, because no case has gone to trial and no verdict or settlement has been reached, and neither does anyone claiming causation is proven, since causation has not been established.
How do I start a Tylenol autism claim?
Gather medical records documenting the mother's acetaminophen use during pregnancy and the child's autism or ADHD diagnosis, then seek a free consultation with a product-liability attorney experienced in multidistrict litigation. Most work on contingency, meaning they are paid only if the case succeeds, and promptness matters because statutes of limitations vary by state and can be complicated by rules pausing the clock while a child is a minor.